Recombinant human adenovirus type 5 injection
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Recombinant human adenovirus type 5 injection, covering 2023-02-08 to 2023-02-08. Get the full timeline:
Most recent: Clinical Trial Update: Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma [Phase 2]